Hormone receptor assays: Clinical usefulness in the management of carcinoma of the breast

Critical Reviews in Clinical Laboratory Sciences

Volumn 26, Issue 2, 1988, Pages 97-152

  Jordan, V Craig ^a   Wolf, Michael F ^a   Mirecki, Dawn M ^a   Whitford, David A ^a   Welshons, Wade V ^a   Desombre, Eugene R ^b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR;

BREAST TUMOR; REVIEW;

BREAST NEOPLASMS; RECEPTORS, CELL SURFACE; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0024202461     PISSN: 10408363     EISSN: None     Source Type: Journal    
DOI: 10.3109/10408368809106860     Document Type: Article

References (379)

1. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases
2. On oophorectomy in cancer of the breast
3. Analysis of cases in which oophorectomy was performed for inoperable carcinoma of the breast
4. An analysis of 99 cases of inoperable Carcinoma of the breast treated by oophorectomy
5. The influence of castration by roentgen on carcinoma of the breast
6. Estrogen excretion following operative and irradiation castration in case of mammary cancer
7. Further investigations on the origin of tumors in mice. If. On the part played by internal secretion in the spontaneous development of tumors
8. Apparition de cancers de la mamelle chez le souris male, sourmise à des injections de folliculine
9. A synthetic oestrus-exciting compound
10. Synthetic oestrogenic agents without the phenanthrene nucleus
11. Oestrogenic activity of dianol, a dimeride p-propenylphenol
12. Oestrogenic activity of anol: a highly active phenol isolated from the byproducts
13. Oestrogenic activity of certain synthetic compounds
14. Biological effects of the synthetic oestrogenic substance 4:4' dihydroxy-α:β diethlstilbene
15. Apparition d'adénocarcinomes mammaires chez des souís males traiées par une substance oestrogéne synthetique
16. Influence of synthetic oestrogens upon advanced malignant disease
17. Synthetic oestrogens in mammary cancer
18. Inhibition of human mammary and prostatic cancer by adrenalectomy
19. Adrenalectomy and oophorectomy in treatment of advanced carcinoma of the breast
20. Characteristics of adrenal-dependent mammary cancers
21. Estrogen excretion in women with mammary cancer before and after adrenalectomy
22. Evaluation of endocrine therapy for advanced breast cancer
23. Urinary estrogens and related compounds in postmenopausal women with mammary cancer: effect of cortisone treatment
24. Hypophysectomy in man: experience in metastatic cancer of the breast
25. Management of metastatic mammary cancer
26. Tissue localization and excretion routes of radioactive diethylstilbestrol
27. The metabolic pattern of 14C-diethylstilbestrol
28. The excretion of microgram doses of hexestrol by rabbits and rats
29. Selective accumulation of tritium-labeled hexoestrol by the reproductive organs of immature female goats and sheep
30. Basic guides to the mechanism of estrogen action
31. The influence of sex hormones on mammary tumors induced by 2-acetaminofluorene
32. Development of adenocarcinoma of the breast in the Wistar rat following the gastric instillation of methylcholanthrene
33. Influence of sex hormones on the incidence and form of tumors produced in male or female rats by gastric instillation of methylcholanthrene
34. Rapid induction of mammary carcinoma in the rat and the influence of hormones on the tumors
35. Mammary carcinogenesis by 3-methylcholanthrene. 1. Hormonal aspects in tumor induction and growth
36. Effect of dose and hormones on tumor production in rats given emulsified 9, 10-dimethyl-l,2-benzanthracene intravenously
37. Mammary cancer induced by a single feeding of polynuclear hydrocarbons and its suppresion
38. 3H]oestradiol by dimethylbenzanthracene-induced rat mammary tumors
39. 3H]oestradiol-17β in dimethylbenzanthracene-induced rat mammary adenocarcinoma and other tissues
40. Biochemical pharmacology of antiestrogen action
41. The uptake of tritiated oestradiol by dimethylbenzanthracene-induced mammary tumors of the rat
42. Studies with tritium-labelled hexoestrol in advanced breast cancer
43. The binding of estradiol in the uterus: a mechanism for depression of RNA synthesis
44. Stereospecific binding of estrogens in the rat uterus
45. A receptor molecule for estrogen isolated from rat uterus and preliminary characterization
46. A receptor molecule for estrogens studies using a cell-free system
47. Hormone-receptor interactions as a guide to biochemical mechanism
48. Hormone receptors: studies on the interaction of estrogen with the uterus
49. A two-step mechanism for the interaction of estradiol with rat uterus
50. New in vitro studies of estradiol binding in castrated rat uterus
51. Reversible disaggregation of the cytosol binding protein of uterine cytosol
52. Properties of a uterine oestradiol receptor
53. Sulfhydryl groups and estradiol-receptor interaction
54. The estrogen receptor
55. Estrogen receptors in the rat uterus. Multiple forms produced by concentration-dependent aggregation
56. Estrogen-binding protein of the rat uterus
57. Estrogen receptors in the rat uterus. Relationship between cytoplasmic and nuclear forms of the estrogen binding protein
58. The common 90-kd protein component of nontransformed “8S” steroid receptors is a heat-shock protein
59. A protein kinase copurified with chick oviduct progestrone receptor
60. Association of the heat shock protein HS90 with steroid hormone receptors and tyrosine Kinase oncogene products
61. Monoclonal antibodies against a component related to soluble estrogen receptor
62. Immunoradiometric studies with monoclonal antibody against a component related to human estrogen receptor
63. The generation of antibodies against partially purified estradiol receptor from human myometrium
64. Estrogen binding substances of target tissue
65. Estrogen control of progesterone receptor in human breast cancer
66. Nuclear mechanisms of estrogen action
67. Estrogen control of progesterone receptor in human breast cancer. Role of estradiol and antiestrogen
68. Actinomycin D prevents nuclear processing of estrogen receptors
69. Characterization of the estrogen receptor and its dynamics in MCF-7 breast cancer cells using a covalently-attaching antiestrogen
70. Estrogen receptor synthesis and turnover in MCF-7 breast cancer cells measured by density shift technique
71. Estrogen receptor replenishment—evidence for receptor recycling
72. Estrogen receptors in different target tissues: similarities of form—dissimilarities of transformation
73. A re-examination of the interaction of estradiol with target cell receptors
74. Estrogen receptors. Unoccupied sites in nuclei of a breast tumor cell line
75. Equilibrium. The intracellular distribution of steroid receptors
76. Characterization of a unique population of unfilled estrogen-binding sites associated with the nuclear fraction of immature rat uteri
77. Towards a new model for the mechanism of action of steroids
78. Rat uterine growth and induction of progesterone receptor without estrogen receptor translocation
79. Monoclonal antibodies to estrophilin: probes for the study of estrogen receptors
80. Monoclonal antibodies to human estrogen receptors
81. Monoclonal antibodies as probes for estrogen receptor detection and characterization
82. Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells
83. An immunocytochemical method for demonstrating estrogen receptor in human uterus using monoclonal antibodies to human estrophilin
84. Immunoelectron microscopic localization of estrogen receptor with monoclonal estrophilin antibodies
85. Heterogeneity of nuclear steroid hormone receptors with an emphasis on unfilled receptor sites
86. Effects of cytochalasins on mammalian cells
87. Intracellular localization of mouse DNA polymerase α
88. Nuclear localization of unoccupied oestrogen receptors
89. Estrogen receptor distribution in breast cancer cell lines
90. Human cell line from pleural effusion derived from breast carcinoma
91. Estrogen receptor in a human cell line (MCF-7) from breast carcinoma
92. Establishment and characterization of a cell line of human breast carcinoma origin
93. Estrogen control of prolactin synthesis in vitro
94. Direct and reversible inhibition of estradiol-stimulated prolactin synthesis by antiestrogens in vitro
95. Estrogen and the growth of breast cancer: new evidence suggests indirect action
96. Evidence for a direct growth stimulating effect of estradiol on human MCF-7 cells in vivo
97. Estrogenic effect of tamoxifen and its derivatives on the proliferation of MCF-7 human breast cancer cells
98. The effects of estrogens and antiestrogens on hormoneresponsive human breast cancer in long-term tissue culture
99. Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture
100. Adaption of estrogen-dependent MCF-7 cells to low estrogen (Phenol red-free) culture
101. Autocrine secretion and malignant transformation of cells
102. Autocrine growth factors and cancer
103. Rat transforming growth factor Type 1: structure and relation to epidermal growth factor
104. Synthesis of biologically active transforming growth factor. I
105. Induction of epidermal growth factor related polypeptides by 17β-estradiol in MCF-7 human breast cancer cells
106. Estrogen-induced growth factors of breast cancer cells partially replace estrogen to promote tumor growth
107. H oncogene
108. Evidence that transforming growth factor β is a hormonally regulated negative growth factor in human breast cancer cells
109. Estrogen inhibition of a Mr 39,000 glycoprotein by human breast cancer cells
110. Antiestrogen stimulation of the production of a 37,000 molecular weight secreted protein and estrogen stimulation of the production of a 32,000 molecular weight secreted protein in MCF-7 human breast cancer cells
111. Progesterone receptor in the chick oviduct: an immunohistochemical study with antibodies to distinct receptor components
112. 3, cells
113. A secreted glycoprotein induced by estrogen in human breast cancer cell lines
114. Release of estrogen-induced glycoprotein with a molecular weight of 52,000 by breast cancer cells in primary culture
115. Estradiol stimulates synthesis of a major intracellular protein in human breast cancer cell line MCF-7
116. 2 RNA and the 52- and 160-kilodalton proteins in MCF-7 cells and two tamoxifen-resistant sublines
117. Use of two MCF-7 cell variants to evaluate the growth regulatory potential of estrogen-induced products
118. Integral membrane glycoprotein properties of the prohormone pro-transforming growth factor α
119. Epidermal growth factor stimulation of human breast cancer cells in culture
120. Receptor binding and processing of epidermal growth factor by human breast cancer cells
121. Characterization of epidermal growth factor receptor and action on human breast cancer cells in culture
122. Resistance to antiestrogen therapy
123. Technical pitfalls, methodological improvements and quality control of steroid hormone receptor assays
124. 125I]iodoestradiol
125. Routing assays for steroid hormone receptors
126. 3H]-17, 21-dimethyl-19-nor-pregna 4,9-diene-3-,20-dione for the measurement of progesterone receptors in human malignant tissue
127. Measurement of progesterone receptor in human breast tumor using the synthetic progestin 16α-ethy1–21-hydroxy-l9-nor-4-pregna 4-ene-3,20-dione
128. Interference of O.C.T.r` embedding compound with hormone receptor assay
129. Improved sensitivity in the measurement of estrogen receptors in human breast cancer
130. The protection, stabilization and reactivation of estradiol receptors in human myometrial cytosol
131. Sodium molybdate increases the amount of progesterone and estrogen receptor detected in certain breast cancer cytosols
132. Structural similarity of molybdate stabilized steroid receptors in human breast tumors, uteri and leukocytes
133. Characterization and assay of progesterone receptors in human mammary carcinoma
134. A method for determining the sedimentation behaviour of enzymes. Application to protein mixtures
135. Specific estrogen-binding capacity of the cytoplasmic receptor in normal and neoplastic breast tissues of humans
136. Estrogen receptors and breast cancer response to adrenalectomy
137. Similarity of the estrogen receptors in human and rat mammary carcinoma
138. Estrogen receptors in human breast cancer
139. Content of estrogen receptors in human breast cancer
140. Specific receptors of the steroid hormones in breast cancer
141. 3H]tamoxifen in rat uterine cytosols: a comparison of swinging bucket and vertical tube rotor sucrose density gradient analysis
142. Use of the vertical rotor to facilitate estrogen and progesterone receptor analysis
143. Radio-ligand binding assay of specific estrogens using a soluble uterine macromolecule
144. Specific estrogen binding by the cytoplasm of human breast carcinoma
145. Estrogen receptors in human breast cancer. I. Methodology and characterization of receptors
146. Oestradiol receptors in carcinoma and benign disease of the breast: an in vitro assay
147. Estimation of the association constant of the estrogen receptor complex in human breast cancer
148. E.O.R.T.C. Breast Cancer Co-operative Group, Standards for the assessment of estrogen receptors in human breast cancer
149. Estrogen receptors in human breast cancer
150. Oestrogen receptors in breast cancer: a changing concept
151. The attraction of proteins for small molecules and ions
152. Scatchard plots: common errors in correction and interpretation
153. Graphical methods in enzyme chemistry
154. Mathematical analysis of data from receptor assays
155. The Woolf plot is more reliable than the Scatchard plot in analyzing data from hormone receptor assays
156. Human breast tumor estrogen receptor: effects of molybdate and electrophoretic analysis
157. Effect of molybdate on classification of estrogen and progesterone receptor status in human breast cancer
158. Effect of sodium molybdate on protein measurements: quality control aspects of steroid hormone receptor assay
159. Oestrogen receptor assay—limitation of the method
160. Estrogen receptor measurement in low-protein breast cancer cytosols
161. Pitfalls in the dextran-coated charcoal assay of estrogen receptors in breast cancer tissue
162. Measurement of progesterone receptors in human breast cancer biopsies
163. Measurement of progesterone receptors in human breast tumors: comparison of various methods of analysis
164. Estrogen receptor in very small breast tumor specimens: a modified charcoal-gelatin assay
165. Antibodies to estrogen receptor: immunochemical similarity of estrophilin from various mammalian species
166. Antibodies to estrophilin: comparison between rabbit and goat antisera
167. Simple methods for production and characterization of rabbit antibodies to human breast tumor estrogen receptors
168. Immunohistochemical localization of estrogen receptors in human mammary carcinoma using antibodies to the receptor protein
169. Differences between estrogen and antiestrogen receptor complexes from human breast tumors identified with an antibody against the estrogen receptor
170. 3H]monohydroxytamoxifen-estrogen receptor complexes with a monoclonal antibody
171. Abbott monoclonal enzyme immunoassay measurement of estrogen receptors in human breast cancer: a European multicenter study
172. Comparison of immunocytochemical and radioligand binding assays for estrogen receptors in human breast tumors
173. Comparison of monoclonal antibodies and tritiated ligands for estrogen receptor assays in 241 breast cancer cytosols
174. Comparison of immunocytochemical estrogen receptor assay, estrogen receptor immunoassay and radioligand-labeled estrogen receptor assay in human breast cancer and uterine tissue
175. Evaluation of an enzyme immunoassay for estrogen receptors in human breast cancers
176. Determination of estrogen receptor in breast cancer using monoclonal antibody technology: results of a multicenter study in the United States
177. Steroid hormone receptors and human breast cancer
178. Quality control requirements in estrogen receptor determination
179. Comparison of immunocytochemical and steroid-binding assays for estrogen receptors in human breast tumors
180. Immunohistological localization of estrogen receptors in breast cancer with monoclonal antibodies
181. Estrogen receptor analyses correlation of biochemical and immunochemical methods using monoclonal antireceptor antibodies
182. Histochemical detection of estrogen receptors in breast carcinoma: a successful technique
183. Prognostic usefulness of estrogen receptor immunocytochemical assays (ER-ICA) for human breast cancer
184. The use of monoclonal antibodies to estrogen receptors (ER) for immunoperoxidase detection of ER in paraffin sections of human breast cancer tissues
185. Immunocytochemical demonstration of estrogen receptors by monoclonal antibodies in human breast cancer: correlation with estrogen receptor assay by dextran-coated charcoal method
186. Are histochemical methods for estrogen receptors valid?
187. Cytochemical analysis of human breast cancers with sex steroid conjugates. Comparison with biochemical oestrogen receptor
188. Fluorescent ligands used in histochemistry do not discriminate between estrogen receptorpositive and receptor-negative human tumor cell lines
189. Estrophilin and endocrine responsiveness of breast cancer in hormones, receptors and breast cancer
190. Estradiol and progesterone receptor levels in human breast adenocarcinoma in relation to plasma estrogen and progesterone levels
191. Estradiol receptor in human breast cancers throughout the menstrual cycle
192. Estrone and estradiol content in human breast tumors: relationship to estradiol receptors
193. Oestrogen receptors in breast tumors: associations with age, menopausal status and epidemiological and clinical features in 735 patients
194. Relationship of age and menopausal status to estrogen receptor content in primary carcinoma of the breast
195. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer
196. Correlation of estrogen and progesterone receptors with histological differentiation of mammary carcinoma
197. Analysis of estradiol and progesterone receptors in early and advanced breast tumors
198. Oestrogen receptors and breast cancer: current status
199. Pathological findings from the National Surgical Adjuvant Breast Project
200. Multiple estrogen receptor assays in human breast cancer
201. Multiple progesterone receptor assays in human breast cancer
202. Factors affecting estrogen receptors in breast cancer
203. Estrogen receptor protein in multiple tumor specimens from individual patients with breast cancer
204. Oestrogen receptors in breast cancer: a changing concept
205. Estrogen receptors and natural course of breast cancer
206. The variability of estrogen receptors in metastatic breast cancer
207. Distribution of estrogen and progesterone receptors on primary tumor and lymph nodes in individual patients with breast cancer
208. Estrophilin assays in breast cancer: quantitative features and application to the mastectomy specimen
209. Epidermal growth factor receptors in human breast cancer
210. Epidermal growth factor binding by breast tumor biopsies and relationship to estrogen receptor and progestin receptor levels
211. Epidermal growth factor receptors and oestrogen receptors in human breast cancer
212. Receptors for EGF and oestradiol and thymidine kinase activity in different histological subgroups of human mammary carcinomas
213. Quality control of steroid receptor assays in the Netherlands
214. Interlaboratory variability in the determination of estrogen and progesterone receptor content in human breast tumors: quality control in Switzerland
215. Methods of steroid receptor analyses and their quality control in the clinical laboratory
216. Reliability of steroid hormone receptor assays: an international study
217. Estrogen receptor assays: interlaboratory and intralaboratory variation in the measurement of receptors using dextran-coated charcoal technique: a study sponsored by ECOG
218. Precision in estrogen and progesterone receptor assays
219. Standardization of steroid receptor assays in human breast cancer. I. Reproducibility of estradiol and progesterone receptor assays
220. Quality control of estradiol receptor analysis: the United Kingdom experience
221. British interlaboratory quality assessment of steroid receptor assays
222. The Netherlands interlaboratory quality control program of steroid receptor assays in breast cancer
223. Standardization of steroid receptor assays in human breast cancer. II. Samples with low receptor content
224. Inhibition of progesterone receptor activation by sodium molybdate
225. The surgical implications of estrophile protein estimations in carcinoma of the breast
226. Estrogen receptor as an independent prognostic factor for early recurrence
227. Prognostic value of estrogen receptor determinations in patients with breast cancer
228. Estrogen receptor assay in primary breast cancer and early recurrence of the disease
229. Oestrogen receptors and prognosis in early breast cancer
230. Association between steroid hormone receptor status and disease-free interval in breast cancer
231. Disease-free interval and estrogen receptor activity in tumor tissue of patients with primary breast cancer: analysis after long-term follow up
232. The value of estrogen and progesterone receptors in the treatment of breast cancer
233. Relationship of presence of progesterone receptors to prognosis in early breast cancer
234. Estrogen receptor levels and others factors in early recurrence of breast cancer
235. Oestrogen receptors and breast cancer: current status
236. Cancer du sein operable: valeur pronostique du nombre des recepteurs d'estradiol
237. Relationship between primary breast cancer tumor receptor status and patient survival
238. Prognostische Bedeutung von östrogenrezeptoren beim Mammakarzinom
239. Estrogen receptors and breast cancer: prognostic and therapeutic implications
240. Early recurrence in estrogen receptor negative breast carcinomas
241. Prognostic importance of estrogen receptors to select node negative patients for adjuvant chemotherapy
242. Prognostic importance of progesterone receptors (PR) alone or in combination with estrogen receptors (ER) in node negative (N-) breast carcinoma
243. Estrogen receptor: a prognostic factor in breast cancer
244. Estrogen receptor protein in breast cancer as a predictor of recurrence
245. Estrogen receptor quantitation and staging as complementary prognostic indicators in breast cancer: a study of 583 patients
246. Estrogen receptor status as a prognostic indicator for stage I breast cancer patients
247. And the Mammacarcinoom Werkgroep De prognostiche betekenis van onderzoek naar receptaractiviteit voor estradiol in the tumorweefsel van patienten met een primair mammacarcinoom
248. Estrogen receptors in primary breast cancer
249. Influence and significance of certain prognostic factors on survival in breast cancer
250. The estrogen receptor test: a prognostic tool in primary breast cancer
251. Factors associated with prognosis in human breast cancer. III. Estradiol receptors and short-term relapse
252. Progesterone receptors as a prognostic factor in stage II breast cancer
253. The relative importance of estrogen receptor analysis as a prognostic factor for recurrence or response to chemotherapy in women with breast cancer
254. Estrogen receptors and disease-free interval: a dissenting opinion
255. Evaluation of the pathologic and prognostic correlates of estrogen receptors in primary breast cancer
256. Mògliche prognostische Kriterien zur Therapie-Verbesserung beim primären Mamakarzinom
257. Oestrogen receptors, clinical features and prognosis in stage III breast cancer
258. Steroid receptors and prognosis in operable (stage I and II) breast cancer
259. Prognostic role of estrogen receptor determinations in breast cancer
260. Progesterone and estrogen receptors as prognostic variables in breast cancer
261. The correlation between estrogen receptor status, axillary-node metastases and disease-free interval after surgery in primary breast cancer
262. Steroid receptors and survival after first relapse in breast cancer
263. Oestrogen and progestrone receptors and disease-free interval in primary breast cancer
264. Estrogen receptors and long-term prognosis in breast cancer
265. Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary node metastases and histological grading
266. Prognostic value of estrogen receptors in primary breast cancer
267. and the Breast Cancer Prognostic Study Clinical and Pathological Associates, The prognostic value of estrogen receptor determinations in patients with primary breast cancer: an update
268. Prognostic significance of the steroid receptor content in primary breast cancer
269. The association of cytosol oestrogen and progesterone receptors with histological features of breast cancer and early recurrence of disease
270. Prognostic value of estrogen and progesterone receptors in primary breast cancer
271. Estrogen receptor protein of breast cancer as a predictor of recurrence
272. Oestrogen receptors in primary and advanced breast cancer. An eight-year review of 704 cases
273. Relationship between oestrogen-receptor content and histological grade in human primary breast tumors
274. The metabolism of steroid-modifying anticancer agents
275. The pharmacology and clinical uses of tamoxifen
276. Effect of some triphenylethylenes on oestradiol binding in vitro to macromolecues from uterus and anterior pituitary
277. Tamoxifen (ICI46, 474) and the human carcinoma 8S oestrogen receptor
278. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity
279. Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced breast cancer
280. Estrogen responsive proliferation of clonal human breast carcinoma cells in athymic mice
281. Role of hormones in the growth and regression of human breast cancer cells (MCF-7) transplanted into athymic mice
282. Strategies for breast cancer therapy
283. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice
284. Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen
285. Adjuvant tamoxifen treatment of elderly women with stage II breast cancer
286. and Members of the Nolvadex Adjuvant Trial Organization, Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer: interim analysis at four years
287. And Members of the Nolvadex Adjuvant Trial Organization, Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer: analysis at six years
288. Ludwig Breast Cancer Group, Randomized trial of chemoendocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastases
289. A randomized trial of adjuvant tamoxifen in postmenopausal women with axillary node positive breast cancer
290. Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values
291. Should adjuvant tamoxifen be given for several years in breast cancer?
292. Adjuvant tamoxifen for operable carcinoma of the breast: report of clinical trial by the Christie Hospital and Holt Radium Institute
293. The Christie Hospital tamoxifen (Nolvadex) adjuvant trial for operable breast carcinoma—seven-year results
294. Adjuvant tamoxifen in postmenopausal breast cancer: preliminary results of a randomized trial
295. Adjuvant tamoxifen therapy and receptor levels (letter)
296. Use of the DMBA-induced rat mammary carcinoma system for the evaluation of tamoxifen as a potential adjuvant therapy
297. The effectiveness of long-term tamoxifen treatment in a laboratory model for adjuvant hormone therapy of breast cancer
298. Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: problems and potential for future clinical applications
299. Long-term tamoxifen adjuvant therapy in node-positive breast cancer: a metabolic and pilot clinical study
300. Prolonging tamoxifen therapy for primary breast cancer: findings from the National Surgical Adjuvant Breast and Bowel Project Clinical Trial
301. Endocrine aspects in adjuvant therapy for early breast cancer Endocrine Therapy of Breast Cancer: Concepts and Strategies
302. Antiestrogen cytotoxic chemotherapy and bacillus Calmet-Guerin vaccination in stage II breast cancer: seventy-two-month follow-up
303. Combination chemotherapy as an adjuvant treatment in operative breast cancer
304. Postoperative chemotherapy and chemohormonal therapy in women with node-positive breast cancer
305. Treatment of primary breast cancer with chemotherapy and tamoxifen
306. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer
307. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial
308. Systemic adjuvant therapy in the treatment of primary operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Experience
309. Mechanism of action of adjuvant chemotherapy in early breast cancer
310. Adjuvant chemotherapy in breast cancer
311. L-Phenylalanine mustard (LPAM) in the management of primary breast cancer: a report of early findings
312. Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer
313. Ovarian function in patients receiving adjuvant chemotherapy for breast cancer
314. Pituitary-ovarian function in breast cancer patients on adjuvant chemoimmunotherapy
315. Hormonal regulation of the menstrual cycle in women with breast cancer: effect of adjuvant chemotherapy
316. Effects of adjuvant chemohormonal therapy on the ovarian and adrenal function of breast cancer patients
317. Long-term follow up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's disease
318. Endocrine consequences of CMF adjuvant therapy in premenopausal and postmenopausal breast cancer patients
319. Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer
320. Ludwig Breast Cancer Study Group, Adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in 1 to 3 axillary lymph nodes: a randomized trial
321. A clinical trial of an artificial menopausal in carcinoma of the breast
322. Ovarian irradiation and prednisone following surgery and radiotherapy for carcinoma of the breast
323. Prophylactic oophorectomy in operable instances of carcinoma of the breast
324. Results of a clinical trial concerning the worth of prophylactic oophorectomy for breast carcinoma
325. Prophylactic oophorectomy in the treatment of carcinoma of the breast
326. Ludwig Breast Cancer Study Group, Chemotherapy with or without oophorectomy in high-risk premenopausal patients with operable breast cancer
327. Estrogen receptors in human breast cancer: an overview
328. Antiestrogens in the treatment of breast cancer
329. A review of the international clinical experience with tamoxifen
330. Progesterone binding in the mouse and rat uterus
331. Progesterone-binding proteins of rat and rabbit uteri
332. Progesterone receptor in rabbit uterus. I. Characterization and estradiol-17β augmentation
333. Mechanism regulating the concentration and conformation of progesterone receptor(s) in the uterus
334. Predicting response to endocrine therapy in human breast cancer: a hypothesis
335. Progesterone receptors and human breast cancer
336. Progesterone and estrogen receptors in Japanese breast cancer
337. The value of progesterone receptor assays in the management of advanced breast cancer
338. Relationship between steroid receptors and response to endocrine therapy and cytotoxic chemotherapy in metastatic breast cancer
339. Relation of tumor content of estrogen and progesterone receptors with response of patients to endocrine therapy
340. Estrogen and progesterone receptors in the prediction of response of breast cancer to endocrine therapy
341. Comparison of sex steroid receptor analyses and carcino-embryonic antigen with clinical response to hormone therapy
342. Steroid hormone receptors and clinical usefulness in human breast cancer
343. The clinical value of multiple steroid receptor assays in breast cancer management
344. The role of progesterone receptors in the management of advanced breast cancer
345. Predicting treatment response in breast cancer using urinary discriminant ratio and receptor assay
346. Megestrol acetate in advanced breast cancer: response rate related to estrogen receptor and progesterone receptor levels
347. Lack of estrogen receptor is associated with an increased response rate to cytotoxic chemotherapy in metastatic breast cancer
348. Association between steroid hormone receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer
349. Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer
350. Steroid receptors in breast cancer
351. Chemotherapy of disseminated breast cancer: current status and prospects
352. Effects of tamoxifen on estrogen and progesterone receptors in human breast cancer
353. Changes in multiple or sequential estrogen receptor determinations in breast cancer
354. Increase of progesterone receptor by tamoxifen as a hormonal challenge test in breast cancer
355. Presurgical radiotherapy decreases the concentrations of estrogen and progesterone receptors in human breast cancer: a 200-patient study
356. Changes of steroid receptor content by chemotherapy and/or endocrine therapy in advanced breast cancer
357. Combination treatment with tamoxifen and aminoglutethimide in advanced breast cancer
358. Modulation of natural killer cell activity by tamoxifen in stage I postmenopausal breast cancer
359. Host factors affecting the growth of carcinogen-induced rat mammary carcinomas: a review and tribute to Charles Brenton Huggins
360. Milan Adjuvant Trials for stage I-II breast cancer
361. Adjuvant chemotherapy (AC) for T1–2, No, Mo estrogen receptor (ER) negative breast cancer preliminary results of a randomized trial
362. Adjuvant chemotherapy in node-negative breast cancer patients
363. University of Arizona adjuvant breast cancer trials for node negative and node positive patients
364. Distribution of an estrogen-induced protein with a molecular weight of 24,000 in normal and malignant human tissues and cells
365. Monoclonal antibody identification and characterization of a Mr 43,000 membrane glycoprotein associated with human breast cancer
366. Human breast cancer correlation of relapse and survival with amplification of the HER-2/neu oncogene
367. Definition of antigenic heterogeneity and modulation among human mammary carcinoma cell populations using monoclonal antibodies to tumor-associated antigens
368. Radiolocalization of human mammary tumors in athymic mice by a monoclonal antibody
369. Generation of monoclonal antibodies reacting with normal and cancer cells of human breast
370. Immunochemical analysis of the determinant recognized by a monoclonal antibody (MBrl) which specifically binds to human mammary epithelial cells
371. Tissue distribution of an epithelial and tumor-associated antigen recognized by monoclonal antibody F36/22
372. Generation and immunohistological characterization of human monoclonal antibodies to mammary carcinoma cells
373. Relationship of monoclonal antibody binding to estrogen and progesterone receptor content of breast cancer
374. Evaluation of monoclonal antibodies for the development of breast cancer immunotoxins